Fri, July 2, 2021
Thu, July 1, 2021
Wed, June 30, 2021

Amit Hazan Downgraded (BVS) to Hold and Decreased Target to $19 on, Jul 1st, 2021

Amit Hazan of Goldman Sachs, Downgraded "Bioventus Inc." (BVS) to Hold and Decreased Target from $20 to $19 on, Jul 1st, 2021.

Amit has made no other calls on BVS in the last 4 months.



There are 3 other peers that have a rating on BVS. Out of the 3 peers that are also analyzing BVS, 0 agree with Amit's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Amit


  • David Lewis of "Morgan Stanley" Maintained at Buy with Increased Target to $19 on, Monday, April 19th, 2021
  • Kyle Rose of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $23 on, Monday, March 8th, 2021
  • Robbie Marcus of "JP Morgan" Initiated at Buy and Held Target at $17 on, Monday, March 8th, 2021